Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50M
QNRX sits 92% above its 52-week low of $3.25 on light trading volume (0.1× avg).
Summary
Quoin Pharmaceuticals announced a private placement financing of up to $50 million. The company has a market cap of approximately $10.4 million, so this financing is highly dilutive and could significantly increase the share count. The terms of the placement, including pricing and investors, were not disclosed in the headline. This follows positive interim data from the Phase 2/3 study of QRX003 in Netherton Syndrome reported earlier today, which may have provided a favorable backdrop for the raise. The financing addresses the going concern doubt reiterated in the Q2 10-Q filed on August 14, 2026.
At the time of this announcement, QNRX was trading at $6.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.4M. The 52-week trading range was $3.25 to $41.80. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.